VERVE THERAPEUTICS INC's ticker is VERV and the CUSIP is 92539P101. A total of 128 filers reported holding VERVE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.34 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $658,452 | -35.4% | 49,657 | -8.6% | 0.00% | 0.0% |
| Q2 2023 | $1,018,987 | +83.3% | 54,346 | +41.0% | 0.00% | 0.0% |
| Q1 2023 | $555,833 | -21.7% | 38,546 | +5.0% | 0.00% | 0.0% |
| Q4 2022 | $710,243 | -27.8% | 36,705 | +28.1% | 0.00% | 0.0% |
| Q3 2022 | $984,000 | +415.2% | 28,644 | +128.5% | 0.00% | – |
| Q2 2022 | $191,000 | -30.8% | 12,533 | +3.4% | 0.00% | – |
| Q1 2022 | $276,000 | -31.3% | 12,121 | +11.5% | 0.00% | – |
| Q4 2021 | $402,000 | – | 10,870 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,008,809 | $26,636,807 | 17.30% |
| Alphabet Inc. | 10,549,086 | $139,880,880 | 8.98% |
| Casdin Capital, LLC | 2,954,710 | $39,179,455 | 4.34% |
| MPM BioImpact LLC | 857,940 | $11,376,284 | 3.04% |
| Saltoro Capital, LP | 66,500 | $881,790 | 0.79% |
| ARK Investment Management | 5,200,567 | $68,959,525 | 0.53% |
| Redmile Group, LLC | 809,777 | $10,737,643 | 0.51% |
| Ikarian Capital, LLC | 2,413 | $3,199,638 | 0.38% |
| Logos Global Management LP | 215,000 | $2,850,900 | 0.38% |
| Nikko Asset Management Americas, Inc. | 2,147,243 | $28,429,497 | 0.34% |